FCE Abeokuta shut as health worker dies of COVID-19 – TheCable

The Federal College of Education, Osiele, Abeokuta, Ogun state capital, has been shut down following the death of a health worker who contracted COVID-19.

In a statement on Friday, Adedayo Adebayo, registrar of the institution, said two other workers at the medical centre also tested positive for the disease.

He added that the infected workers are already undergoing treatment.

A report carried out attributed the cause of death of one of the medical personnel that transited to immortality lately to complications that arose from COVID-19, he said.

Regrettably, the two other staff of the medical centre similarly tested positive to the viral infection and have been placed on isolation and undergoing treatment.

Arising from this untoward development, it is incumbent on the college management to immediately close down the college so as to forestall further spread of the virus.

He advised everyone who had been in contact with the affected medical workers to subject themselves to COVID-19 test.

The college management further advises everyone that has had recent contact with the affected medical personnel to subject themselves to COVID-19 test in order to ascertain their health status and to seek necessary medical intervention, he said.

The management condoles with the bereaved family and the college community and prays that God grants all the succour to bear the irreparable loss.

It also prays for the speedy and total recovery of the affected staff and commits all other staff and students of the College into the care and protection of the Almighty as we all stay safe to outlive this trying period.

See more here:
FCE Abeokuta shut as health worker dies of COVID-19 - TheCable

TV tonight: #MeToo in the music industry – The Guardian

On the Record 9pm, Sky Documentaries

This documentary on the allegations of sexual harassment against the music executive Russell Simmons has had a rocky path to the screen since Oprah Winfrey dropped her support for the film in January, meaning it lost its Apple distribution deal. Yet the forceful testimony from A&R exec Drew Dixon on Simmonss alleged harassment while she was working for the pioneering hip-hop label Def Jam in the 90s makes for convincing viewing, adding to the chorus of #MeToo movement voices coming from the music industry. Ammar Kalia

To help tennis fans cope with withdrawal during what would have been peak Wimbledon, Sue Barker presents this in-depth tribute to the wiry super-Scots career, from his early successes to that rollercoaster summer of 2012. Concludes tomorrow on BBC One at 2.05pm. Graeme Virtue

Airing on the most aptly named of channels, a TV premiere for this doc about how the Fab Four changed pop music, and the planet. With the help of archive footage and interviews, we see how the band transformed areas as disparate as pacifism and fashion. Hannah J Davies

Decent dramatic reconstructions and high-end academic talking heads power this three-part bio, which starts by outlining the series of bloody fiascos that defined George Washingtons early military career before a stroke of luck and his own talent for spin set him on course for immortality. Jack Seale

New York in the 1980s is displayed in all its hedonistic and grimy glory in this new doc exploring the life and work of the artist Keith Haring. Featuring some of his final interviews before his untimely death in 1990, the film charts his instrumental role in placing street art in to the confines of the gallery. AK

A schadenfreude-fuelled look at the tabloid disasters that have followed the former royal couple Sarah Ferguson and Prince Andrew. From early rumours of extramarital affairs to Fergies undercover stings and Andrews catastrophic defence of Jeffrey Epstein. AK

Magic Magic, 1.25am, Film4

After their peyote-fuelled Crystal Fairy & the Magical Cactus, director Sebastin Silva and Michael Cera reunite for this creepy tale of mental breakdown. Cera plays Brink, one of a bunch of travellers at a holiday cabin in Chile who make life miserable for fragile outsider Alicia (Juno Temple). Paul Howlett

Premier League Football: Leicester City v Crystal Palace, 2.30pm, Sky Sports Main Event/Pick. Free-to-air clash.

Premier League Football: Wolverhampton Wanderers v Arsenal, 5.15pm, Sky Sports Main Event. Live from Molineux.

Premier League Football: Chelsea v Watford, 7.45pm, Sky Sports Main Event. Stamford Bridge head-to-head.

Read this article:
TV tonight: #MeToo in the music industry - The Guardian

Madhya Pradeshs new cabinet shows that a slow Congressisation of the BJP is happening – ThePrint

Text Size:A- A+

New Delhi: The newly-formed Madhya Pradesh cabinet signals the Congressisation of the BJP, ThePrints editor-in-chief Shekhar Gupta said in episode 512 of Cut The Clutter.

An analysis of the cabinet, and where the loyalty of its members lie, shows that MP Chief Minister Shivraj Singh Chouhan has been cut to size. In fact, he has been rendered a lame duck whos also been kneecapped.

Fourteen of the 33 cabinet members are former Congress leader Jyotiraditya Scindias loyalists; they had defected to the BJP with Scindia back in March. This means more than 40 per cent of the people, who arent even members of the House yet, have been made ministers.

Three others are loyalists of BJPs Narottam Mishra while three are loyalists of the partys national general secretary Kailash Vijayvargiya. This leaves just 13 ministers who are actually CM Chouhans loyalists, which means he has very little space to do or say anything.

But it isnt just Madhya Pradesh which is showing these signs. Of the 17-NDA ruled states, BJP has its chief ministers in 12, but a closer look reveals a slow move towards a complete Congressisation of the BJP.

For one, this indicates the rise of a high-command culture in the BJP, just like that of the Congress. Only one person or a couple of people own that high command space similar to how the Congress is presently run by just a few people, such as Rahul Gandhi and Sonia Gandhi.

This also shows that the BJP now has very weak CMs as well as cabinet ministers. This is because all the power within the party emanates from one source.

One of the main reasons why Prime Minister Narendra Modi came to power with such a resounding mandate in 2014 was due to the fact that the BJP had built very strong Chief Ministers who could always swing elections in their states for him. But six of these strong CMs are nowhere to be seen now.

Former Rajasthan CM Vasundra Raje is out of power as is former Chhattisgarh CM Raman Singh.

Gujarat had Narendra Modi as its powerful vote-catching CM, but his shift to Delhi moved that power with him. In Maharashtra, Nitin Gadkari, who could swing elections single-handedly, has now been sidelined.

In Madhya Pradesh, Chouhan has also been sidelined, cut to size and rendered powerless despite being the CM.

On Wednesday, at the swearing-in ceremony, he cryptically commented that amrit (nectar of immortality) comes out of the churning of the ocean as Shiva consumes vish (poison), in whatmay be a metaphorical reference to himself.

Other BJP-ruled states signal a similar trend. The formula of keeping your chief minister reduced to a nobody who gets instructions from Delhi for anything he wants to do is being repeated in all the states.

For instance, Assams CM Sarbananda Sonowal is seen to have very little power. In fact, it is the Health Minister Himanta Biswa Sarma who is considered the face of the Assam government. He is also seen as the face of the BJP in all of the Northeast. He won the Northeast for the BJP.

In Haryana, Manohar Lal Khattar has had to share power with his deputy and JJP leader Dushyant Singh Chuatala, after the two parties were forced to form a coalition government. Cabinet minister Anil Vij too occupies a very important, powerful position in the state government.

In Gujarat, CM Vijay Rupani is remote-controlled from New Delhi, which is a well-known fact.

Manipur CM Biren Singh was forced to restore the portfolios of his deputy CM, National Peoples Party leader Y. Joykumar Singh, as part of the understanding reached between Union Home Minister Amit Shah and the NPP delegation led by its national president and CM of neighbouring Meghalaya, Conrad Sangma.

This means that while Singh may be the CM, the real authority and power lies with the high command in Delhi.

In Karnataka, B.S. Yediyurappas authority has been undermined time and again, most recently when none of his Rajya Sabha nominees were selected by the party high command, which instead backed those of Yediyurappas rival, B.L. Santosh.

The one exception to this rule is Uttar Pradesh CM Yogi Adityanath. He was seen as a political lightweight with no real following of his own. But the fact is that the way Adityanath has conducted himself has not only made him more of a Hindutva brand ambassador but also a brand ambassador for Modi and Shah. He wasnt chosen to be an exception, but just turned out to be one.

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

Read the rest here:
Madhya Pradeshs new cabinet shows that a slow Congressisation of the BJP is happening - ThePrint

The Supreme Court surprises us with fairness in LGBTQ decision, but will it last? – Lynchburg News and Advance

And if the employer had additional reasons for the firing? No matter, the decision says in a line suitable for immortality. Intentionally burning down a neighbors house is arson, even if the perpetrators ultimate intention (or motivation) is only to improve the view.

Gorsuchs crisp clarity sent some clear signals yet one must cautiously note, no guarantees regarding future outcomes. He laid his argument on textualism, the popular conservative theory that judges should look to the plain text of the law.

That matters in a subject such as LGBTQ rights, since few people were talking about LGBTQ rights in 1964. Yet, at least since the Stonewall riots broke out during a police raid on a gay and transgender bar in New York and launched the gay and lesbian rights movement in 1969, it increasingly has become a matter of common sense that gender protections should include LGBTQ people.

Looking back, it is all the more ironic to recall that sex was included in the law, which was primarily aimed at racial discrimination, as a sort of last-minute poison pill. Staunch Virginia segregationist Rep. Howard Smith slipped it in, figuring that his fellow lawmakers would see the protection of womens rights as way too extreme. Fortunately, the times were a-changing faster than he realized.

But now, we have the era of Donald Trump vowing under his Make America Great Again slogan to change the times back. Trump, who often seems to be more familiar with breaking the Ten Commandments than citing them, nevertheless appealed heavily to religious conservatives. Among other smart moves, he turned to the right-leaning Federalist Society for court recommendations. The phrase But, Gorsuch ... is routinely cited by evangelicals when asked why they give more than 80% approval to Trump in polls.

Read more:
The Supreme Court surprises us with fairness in LGBTQ decision, but will it last? - Lynchburg News and Advance

Owned, Omor and a dystopian masterpiece – The Daily Star

Writers are usually advised to shy away from words like 'masterpiece', 'classic', 'perfect' or other bold terms and such, especially in an industry that tries to promote mediocrity as a given. Quite often, the lack of equipment, manpower and investment is cited as a reason. Yet, the music video for Owned's latest release Omor was perfect for what it set out to accomplish, even though it was made by just one man.

Before getting ahead of myself, Owned is a rock band from Dhaka that has continuously and diligently delivered nothing but excellence for the better part of a decade now. Consisting of A K Ratul, A K Samee, Fasihuddin Ahmed Itmam and Pritom Arefin, their signature, nuanced grunge sound is recognisable in a heartbeat. Yet, their latest music video helps establish new standards for the band.

"From the outset, we did not want to do a live-action music video this time," says frontman A K Ratul, who is also a talented music producer in his own right. "It was quite a hunt, looking for someone who understood our vision and could get the job done." The band came across animator Ali Arman Asgar, and this is where it instantly clicked.

Ali, who is the CEO of Locust Productions, worked a painstaking eight hours a day for four months to turn the concept for Omor into reality. "When the band came to me with the song, I realised that it deals with the theme of immortality. I, myself had been designing what I had planned to be a web-series with similar themes. I thought it would merge pretty well."

The video, powered by live2web, follows the journey of an anthromorphic pig through multiple dystopian realms. It also includes fully-rendered models of the band members themselves. "I took their photos from different angles and rendered them together," shrugged the nonchalant animator, "In the end, it was the rendering that took quite a toll." Even though the scenes were completed in about four months, the making of the video itself took an entire month for Ali's computer. Essentially, just one person accomplished the job of an entire studio full of animators.

"Ali was cordial when it came to our feedbacks," says A K Samee. "We told him to 'go nuts' with the style, but inserted references from our favourite pop-culture phenomenon for ourselves." Samee insisted that even though the easter eggs were put in the video for the band's own amusement, many found them and shared them online. "I am surprised that so many people picked up on those, as it would require multiple re-watches," said the drummer.

Owned shared that the video is the first of a trilogy, that would be made in partnership with Locust Productions. The band is also set to complete their trilogy of albums with Owned 3. "The pandemic has definitely hurt our plans, but we will finish the album as soon as we can," said Ratul. In the meantime, I will enjoy multiple re-watches of Omor.

The rest is here:
Owned, Omor and a dystopian masterpiece - The Daily Star

Doom Patrol 204 Review This Ain’t the X-Men – Batman-News

Note: Wed planned to reviewDoom Patrol as it released episode by episode, but WB surprised us by unleashing the first three episodes at once on June 25, so our reviews will be a little bit out of order.

Im constantly comparingDoom Patrolto everything I know about the X-Men. It sounds like a bad idea, right? To compare this obscure team of nobodies to a group of heroes that transformed Marvel and spawned dozens if not hundreds of different books for the company. Except that every time I do, Doom Patrol wins out for me. I like weird stuff.Doom Patrol is the weirdest stuff. This week, the analog between the two is all at once impossible to miss and yet less substantial than in many previous episodes.Spoilers follow forDoom Patrol Season 2, Episode 4, Sex Patrol. Also, warning for sex words below. Get ready to giggle and blush.

This week is all about what Stewie from Family Guy would describe as a sexy party. The Patrol needs to resuscitate Danny the Street, who became Danny the Brick, and then Danny the broken Brick. Out of ideas, Dr. Caulder throws a hail-mary pass and invites the Dannyzens from last seasons awesome Danny episode. All thew weirdoes and freaks that have found safety with Danny after being shunned by society. Like that episode, this one feels like a huge coming-together for many of the characters, where the Dannyzens self-acceptance forces them to come to terms with things about themselves.

Theres a great moment early on when Flex Mentallo, the muscle superhero, is using his powers to help prepare the house for the party. He flexes this muscle and lights appear over the windows. He flexes that one and streamers appear all over. Rita goes to put up the disco ball, intending to use her powers to mount it, but her powers wont manifest. So far, shes only been able to do it when her self esteem is low or when shes in a very stressful situation. She has very little control over it, other than not turning into a horrifying flesh blob anymore.

This kicks off two of the interesting storylines this week. Dorothy is in the middle of an existential struggle. She knows her father is dying. She knows she loves Danny. But shes also realizing that Danny wasnt simply her friend for the many years she lived within his streets. Danny was her jail. Meanwhile, Rita is realizing that something is stopping her from controlling her powers. Seeing Flex reminds her that the only time shes been clear of mind is when Flex operated his splenius cervicis muscle, which elicited a very specific reaction from the Patrol.

These two storylines expose just how precarious Dorothy is living with the Patrol. Shes stuck not just physically but mentally and emotionally at the age of 11. Despite being over 100 years old, she is quite literally a child living with a bunch of very adult adults.

Dr. Caulder is in an impossible position with Dorothy. On the one hand, if she were to make a wish to the Candlemaker, there could be repercussions of apocalyptic proportions. Shes an 11-year-old in every sense other than her number of literal years on earth, so wishing is just something shes emotionally predisposed to do. On the other hand, Caulder has been keeping a literal child imprisoned for decades while he searches for immortality to outlast his daughter. I suspect the thrust of the season will be Caulder discovering that there are other optionsthat the search for immortality has been a decades-long goose chase. Well see if that bears out. But Ritas storyline shows that this situation cannot last.

Flex Mentallo is, in short, helping Rita work her way through some trauma by causing her to orgasm. But if you remember back to season 1, Flexs splenius cervicis muscle (its on the back of the neck, down near the shoulder) is quite powerful, and caused the entire street and all the Dannyzens to orgasm when he accidentally engaged it. Listen, these sentences are as absurd to write as they are to read.

The intense, amplified orgasms wake up this weeks monster and summon this weeks heroes, and they literally could not be better than they are. The demon Rita accidentally summons is a sex demon called theShadowy Mr. Evans,a being that meditates in a temple in the far east. The Shadowy Mr. Evans has a periscope on his head and can dissolve into shadows. Wherever he goes, wanton lust follows, and soon he arrives at Doom Manor to spice up the party.

As if by magic, though, someone shows up to stop him. It turns out that the Shadowy Mr. Evans, if unleashed, could turn the world in a childless, hedonistic playground. The SeX-Men appear with back-mounted gun packs and libidometers. Theyre named after the X-Men (by a 12-year-old, probably) and themed after the Ghostbusters.

This pairing sums up the tone of Doom Patrol, something Im calling a silly nightmare. The reality of what could happen is legitimately horrifying, but its very silly to describe, and its good for both laughs and action alike.

So far, Im genuinely enjoying this season ofDoom Patrol. The showrunners are finding great ways to investigate and develop each character. Im enjoying Ritas concerted attempts to become a better person, as well as Vics struggles with continuing to be human while living in a body that is A) not is own and B) custom-built for heroism. Janes struggles to live at peace with herself are compelling thanks to not just Diane Guererros great acting but the other actors who portray her personalities when shes in the underground.

And Cliffs struggles would be heartbreaking if he wasnt so defiant and prone to swearing. He struggles to feelanythingwhile trying to cope with the pain of knowing his daughter has grown up without him while he convalesced in his mechanical body for 30 years.

Im also glad to see the Dannyzens back and for the show to continue to develop who and what Danny is. Danny is a protector, and everything about Danny reinforces that.

I want to see the show get into the meat of the story, but its doing so well with these monster-of-the-week episodes in terms of make-up, set design, special effects and story that Im not going to complain. Plus, Im always down for an episode featuring Flex Mentallo, The Muscle Man of Mystery.

Doom Patrol season 2 is airing now on DC Universe.

Link:
Doom Patrol 204 Review This Ain't the X-Men - Batman-News

Can Margot Robbie save Pirates of the Caribbean from irrelevance? – The Guardian

How intriguing that Pirates of the Caribbean should be looking to Margot Robbie to lift the saga from the depths and out, once again, into the West Indian sunlight. The series has regularly dipped its toe into the potentially bountiful narrative trope of the female pirate surviving and thriving in a mans world, with Keira Knightley, Penlope Cruz, Zoe Saldana and, latterly, Kaya Scodelario among those to have swished cutlasses and swung from the rigging.

And yet the saga has had its issues with gender representation. Scodelario spent most of 2017s Dead Men Tell No Tales being ogled by Johnny Depps much older Captain Jack Sparrow. Previously, Knightleys journey from damsel in distress to (briefly) pirate king of the famed nine pirate lords ended with her back on land and spending her days longing for the once-a-decade return of Orlando Blooms tedious Will Turner.

As a fantasy series in which ancient gods prowl the oceans, immortality is real and our barmy buccaneers can switch from life to living death at the touch of a magic gold sovereign, you might think Pirates of the Caribbean would have little need for historical realism. Yet the idea of a female pirate surviving at sea for long without having to disguise herself as a man (like the real-life 18th-century figures Anne Bonny and Mary Read, as well as Cruzs Angelica in 2011s On Stranger Tides) seems even more fanciful than the existence of a fountain of youth. Having a woman on board was often considered to be bad luck during the golden age of piracy, because captains feared their presence would cause crew members to fight among themselves. And yet, it seems highly unlikely that Disney would consider transforming the swashbuckling series into a scurvy seadog take on Albert Nobbs even if that story is surely a fascinating one that will one day be told far away from the world of blockbuster cinema.

Margot Robbie, if she ends up signing on the dotted line, wont exactly be stepping into Depps well-worn boots. There remain separate plans for a reboot in the main Pirate timeline, though it is unclear at this stage whether Captain Jack Sparrow would make an appearance in the wake of Depps on- and off-screen struggles in recent years. If the Robbie project takes off, it is easy to see Disney quietly putting any other plans back in Davy Joness locker to focus on what works. Theres little doubt the studio sees the new film as a star vehicle for the Australian actor, or it would not have hired Robbies Birds of Prey screenwriter Christina Hodson to work on the script.

Hodson also wrote Transformers spinoff Bumblebee, miraculously taking a franchise that was once so macho that you wondered if the Autobots and Decepticons ran on pure testosterone and working it into a gentle, pleasingly complex coming-of-age tale that seemed to have more in common with the Iron Giant, ET or Disneys Big Hero 6. The studio will no doubt be hoping that she can work similar magic on Pirates of the Caribbean, which at its best was a joyous chance to catch top-notch character actors such as Depp, Geoffrey Rush and Ian McShane at the peak of their furniture-chewing powers, but at its worst descended into lazy, sexist retread territory with plots eventually becoming so foggy and convoluted that most of us would rather have joined Joness doomed crew on the Flying Dutchman rather than be forced to unravel them.

See the rest here:
Can Margot Robbie save Pirates of the Caribbean from irrelevance? - The Guardian

Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se…

Hansa grants Sarepta exclusive license to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV).

Under the terms of the license: Hansa will receive a USD 10 million upfront payment and is eligible for up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase and would be eligible for royalties in the high single-digits to mid-teens on any gene therapy sales enabled through pre-treatment with imlifidase in NAb-positive patients.

Lund, Sweden July 2, 2020. Hansa Biopharma (Hansa), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, announced today that it has entered into an agreement with Sarepta Therapeutics Inc. (Sarepta), the leader in precision genetic medicine for rare diseases, through which Sarepta is granted an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy treatment in Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD). The pre-treatment is intended for patients with pre-existing neutralizing antibodies (NAb-positive patients) to adeno-associated virus (AAV), the technology that is the basis for Sareptas gene therapy products.

Sarepta will be responsible for conducting pre-clinical and clinical studies with imlifidase and any subsequent regulatory approvals. Sarepta will also be responsible for the promotion of imlifidase as a pre-treatment to Sareptas gene therapies following potential approval.

Under the terms of the agreement, Hansa will receive a USD 10 million upfront payment, and is eligible for a total of up to USD 397.5 million in development, regulatory and sales milestone payments. Hansa will book all sales of imlifidase, and earn high single-digit to mid-teens royalties on Sareptas incremental gene therapy sales when treating NAb-positive patients enabled through pre-treatment with imlifidase.

Sren Tulstrup, President & CEO of Hansa Biopharma comments,We see significant potential for our enzyme technology in the gene therapy space overall, and we are excited to partner with Sarepta, a leading player in the field, to use the unique features of imlifidase to potentially enable gene therapy treatment in patients who today arent eligible for these breakthrough therapies due to pre-existing neutralizing antibodies in two conditionswith a very high unmet medical need.

Doug Ingram, President & CEO, Sarepta Therapeutics said,As we expand our leadership position in genetic medicine and build out our gene therapy engine, one of Sareptas central ambitions is to find scientific solutions that bring our potentially life-saving therapies to the greatest number of the rare disease patients we serve. One of the current limitations of gene therapy is the inability to treat patients who have pre-existing neutralizing antibodies to the AAV vector. While our AAVrh74 vector has been associated with a low screen out rate for neutralizing antibodies, even that low rate is inconsistent with our mission.

In pre-clinical and clinical models, Hansas technology has shown the ability to clear the IgG antibodies that prevent dosing AAV-based gene therapies. If successful, this could offer the potential of extending our gene therapy treatments to DMD and LGMD patients who would otherwise have been denied access due to pre-existing antibodies.

Hansa Biopharma will be hosting a conference call with President & CEO Sren Tulstrup, CSO & COO Christian Kjellman and CFO Donato Spota.

Conference Call Partnership agreement with Sarepta TherapeuticsA conference call will take place July 2nd, 2020 at 10:00am CET. The audio cast will be recorded and subsequently be available on the Hansa website https://hansa.eventcdn.net/202007

Participants dial-in numbersSE: + 46 81 241 09 52UK: + 44 203 769 6819US: + 1 646 787 0157

This is information that HansaBiopharma AB is obliged to makepublic pursuant to the EU MarketAbuse Regulation.

About imlifidaseImlifidase is a unique antibody-cleaving enzyme originating from Streptococcus pyogenes that specifically targets IgG and inhibits IgG-mediated immune response. It has a rapid onset of action, cleaving IgG-antibodies and inhibiting their activity within hours after administration. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020.Hansa has also reached an agreement with the FDA on a regulatory path forward for imlifidase in kidney transplantation of highly sensitized patients in the U.S. and has three ongoing phase 2 trials in autoimmune diseases and post-transplant indications.

About gene therapy and neutralizing antibodiesGene therapy is a growing and revolutionizing treatment technology in which healthy gene sequences are inserted into cells of a patient. The treatments are potentially curative in monogenic diseases like hemophilia and muscular dystrophy through a single dose. Harmless recombinant viruses are used to carry the healthy genes into the cell. Due to the partial viral origin of the gene therapy constructs, a certain subset of patients carry neutralizing anti-AAV antibodies towards gene therapy products, depending on what AAV serotype being used, forming a barrier for treatment eligibility.Antibodies prevent effective transfer of healthy gene sequence and can be a safety concern. Imlifidase as a pre-treatment may have the potential to eliminate neutralizing antibodies prior to gene therapy. Similarly, imlifidase may have the potential to enable any potentially necessary re-dosing of gene therapy for all patients.

About Duchenne Muscular Dystrophy (DMD)Duchenne muscular dystrophy is a rare genetic disease caused by mutation in the DMD gene, encoding for the protein dystrophin. Duchenne is an irreversible, progressive disease that causes the muscles in the body to become weak and damaged over time. It is eventually fatal and there is no cure. DMD affects one in 3,500 to 5,000 males born worldwide (approximately 400-500 annual cases in the US) and causes muscles in the body to become weak and most patients use wheelchair by the age of 12.

About Limb-Girdle Muscular Dystrophy (LGMD)Limb-girdle muscular dystrophy or (LGMD) is a genetically and clinically heterogeneous group of rare muscular dystrophies. It is characterised by progressive muscle wasting which affects predominantly hip and shoulder muscles. LGMD has an autosomal pattern of inheritance and currently has no known cure or treatment. It can be caused by a single gene defect that affects specific proteins within the muscle cell, including those responsible for keeping the muscle membrane intact. LGMD has a global prevalence of approximately 1.63 per 100,000 individuals worldwide.

For further information, please contact:Klaus Sindahl, Head of Investor RelationsHansa Biopharma Mobile: +46 (0) 709-298 269E-mail: klaus.sindahl@hansabiopharma.com

About Hansa BiopharmaHansa Biopharma is leveraging its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.The Companys lead product candidate, imlifidase, is a unique antibody-cleaving enzyme that potentially may enable kidney transplantation in highly sensitized patients with potential for further development in other solid organ transplantation and acute autoimmune indications. CHMP/EMA has adopted a positive opinion, recommending conditional approval of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2020. Hansas research and development program is advancing the next generation of the Companys technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.Hansa Biopharma is based in Lund, Sweden and also has operations in Europe and US.

Read the rest here:
Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se...

Movers & Shakers, July 3 | BioSpace – BioSpace

AVROBIO: On Monday, clinical-stage gene therapy company AVROBIO, headquartered in Massachusetts, announced the appointment of Kim Raineri as chief manufacturing and technology officer.

I am thrilled to join AVROBIO, a leader in lentiviral gene therapy and a true pioneer in driving manufacturing advances that address the gene therapy fields need for faster, more scalable and more automated production, Raineri said. The AVROBIO team has created a state-of-the-art gene therapy platform and is clearly committed to continuous innovation on behalf of the patient communities they strive to serve. I am excited to contribute to that work.

Raineri will be replacing AVROBIO co-founder Kim Warren in the position, who will be retiring at the end of July. Before joining AVROBIO, Raineri served as the vice president of operations for Nikon CeLL Innovation Co.

Scenic Biotech: On Wednesday, Netherlands-based Scenic Biotech announced the appointment of their new chief executive officer. Newly appointed CEO Oscar Izeboud brings more than 20 years of life sciences and finance industry experience.

Prior to joining Scenic, Izeboud served as managing director at NIBC Bank in Amsterdam, where he led its corporate finance and capital markets team with a focus on innovation and growth companies.

Former acting CEO and scientific co-founder Sebastian Nijman takes on the role of chief scientific officer.

Akari Therapeutics: Biopharmaceutical company Akari Therapeutics on Wednesday announced the appointment of Torsten Hombeck as chief financial officer and a member of the company's executive team.

Torsten brings a deep understanding of financial strategy, the capital markets and business development to Akari. We are delighted to have him as a permanent member of Akaris executive leadership team," said Clive Richardson, Chief Executive Officer of Akari Therapeutics. "His appointment comes at a time of significant company opportunity and growth. His business and financial expertise will be instrumental in helping us to further develop the Company."

Hormbeck joins Akari with over 20 years of biopharmaceutical industry experience in financial and strategic planning.

Sarepta Therapeutics: Earlier this week, Cambridge-based Sarepta Therapeutics announced the retirement of Sandy Mahatme, the company's executive vice president, chief financial officer and chief business officer. Mahatme will be leaving the company effective July 10.

The Sarepta from which Sandy retires is a very different one from the organization he joined as our chief financial officer some eight years ago. And the Sarepta of today a financially solid biotechnology organization with perhaps the industrys deepest and most valuable pipeline of genetic medicine candidates with the potential to extend and improve lives would not have been possible without Sandys business acumen and dedication, said Doug Ingram, president and chief executive officer of Sarepta Therapeutics.

Sarepta has launched a search to identify the future chief financial officer.

BioMarin: On June 29, BioMarin, a global biotechnology company, announced a pair of promotions. Brian Mueller was promoted to executive vice president, chief financial officer and Andrea Acosta was promoted to group vice president, chief accounting officer.

Mueller has been with BioMarin since 2002, during which he has taken on roles of increasing responsibility. Acosta has been with BioMarin since 2017 as vice president, corporate controller.

Theravance Biopharma: Dublin-based Theravance Biopharma on Thursday announced the appointment of Deepika Pakianathan to its Board of Directors. Pakianathan serves as a managing member at Delphi Ventures, a venture capital firm focused on biotechnology and medical device investments.

"We are honored to welcome Dr. Pakianathan to our board of directors," said Rick Winningham, chief executive officer of Theravance. "We believe her vast experience in the biotechnology sector, translating breakthrough science and taking important therapies from pipeline to patients, will further enhance our already talented Board of Directors."

Novavax: On Thursday, Maryland-based Novavax announced the appointment of Frank Czworka as senior vice president, global sales. Czworka will be responsible for leading sales planning and distribution for the company. He brings more than 20 years of biopharmaceutical experience to the company, with his most recent experience being as vice president, global customer enngagement at U.S. Pharmacopeia.

Novavax also announced the promotion of Brian Webb to senior vice president, manufacturing. Webb will be responsible for overseeing antigen manufacturing and supply activities in support of the company's vaccine candidates. Webb has been with Novavax since May 2014.

eGenesis: On Wednesday, Massachusetts-based eGenesis announced that it appointed Peter Hanson as chief operating officer. Hanson will be in charge directing eGenesis' day-to-day organizational and operational activities including production and manufacturing.

Peter is a highly experienced biopharmaceutical executive across multiple disciplines, which will be critical to support our next phase of growth as we integrate production and R&D, said Paul Sekhri, President and Chief Executive Officer of eGenesis. Peters operational leadership and veterinary knowledge will help us accelerate our product development as we move closer to IND filing for human clinical studies. We are very grateful for Kenneth Fans many contributions as our founding COO. I am delighted that he will continue to serve as an advisor to the company.

Go here to read the rest:
Movers & Shakers, July 3 | BioSpace - BioSpace

The Future of Medicine Is Bespoke – Fair Observer

There was a time when modern medicine was primitive. There were no antibiotics, so every infection took its own course, leading to decline in health. Hypertension and diabetes were largely untreatable. X-ray was new, and remedies had changed but little from medieval times. No one ever embarked on the goodness of preventative treatment, not to speak of predictive medicine, beyond taking a distasteful cod liver oil capsule.

During the last hundred years, modern medicine has undergone a sea change. Just think of it an ever-expanding repertoire of medicines, high-tech procedures, therapies and reams of clinical data to employ when one gets sick. Yet modern medicine remained (in)complete, notwithstanding the therapeutic advances.

READ MORE

Things are now changing thanks to the integration of all such advances, from how a persons diet interacts with ones unique genetic profile to how environmental pollutants affect our thinking, not to speak of preventative medical approaches in health and wellness. The bigperestroikahas begun, and it is poised to transform health care for a growing number of people in the near future. Welcome to a whole new world of personalized, bespoke medicine.

Personalized medicine is, in essence, tailored or customized medical treatment. It treats while keeping in mind the unique, individual characteristics of each patient, which are as distinct as ones fingerprint or signature. It also includes scientific breakthroughs in our understanding of how a persons unique molecular and genetic profile makes them susceptible to certain illnesses. Personalized medicine expands our ability to envisage medical treatments that would not only be effective but also safe for each patient while excluding treatments that may not provide useful objectives.

Personalized medicine is, in simple terms, the use of new methods of molecular scrutiny. It is keyed to help better manage a patients illness or their genetic tendency toward a particular illness or a group of diseases. In so doing, it aims to achieve optimal therapeutic outcomes by helping both clinicians and patients choose a disease management approach that is likely to work best in the context of the patients unique genetic and environmental summary. In other words, it allows to accurately diagnose diseases and their sub-types while prescribing the best form and dose of medication most suited to the given patient.

Personalized, or precision, medicine is not rocket science it is, in essence, an extension of certain traditional approaches to understanding and treating disease. What jazzed up the therapeutic fulcrum of personalized medicine are tools that are more precise. This is what also offers clinicians better insights for selecting a treatment protocol based on a patients molecular profile. Such a patient-specific methodology, as has been practiced for long in certain complementary and alternative medical (CAM) or integrative approaches, not only curtails harmful side effects but also leads to more successful outcomes, including reduced costs in comparison to the current trial-and-error approach to treatment, which has distressingly come to the fore during these extraordinary and unprecedented times of COVID-19.

It is still early days, but the fact remains that personalized medicine has changed the old ways of how we all thought about, identified and managed health issues. As personalized medicine increasingly bids fair to an exciting journey in terms of clinical research and patient care, its impact will only further expand our understanding of medical technology.

What personalized medicine has done is bring about a paradigm shift in our thinking about people in general and also specifically. We all vary from one another what we eat, what others eat, how we react to stress or experience health issues when exposed to environmental factors. It is agreed that such variations play a role in health and disease. It is also being incrementally accepted that certain natural variations found in our DNA can influence our risk of developing a certain disease and how well we could respond to a particular medicine.

All of us are unique individuals, perhaps with the exemption of identical twins, albeit the genomes are unique in them, too. While we are genetically similar, there are small differences in our DNA that are unique, which also makes us distinctive in terms of health, disease and our response to certain medicinal treatments.

Personalized medicine is poised to tap natural variations found in our genes that may play a role in our risk of getting or not getting certain illnesses, along with numerous external factors, such as our environment, nutrition and exercise. Variations in DNA can, likewise, lead to differences in how medications are absorbed, metabolized and used by the body. The understanding of such genetic variations and their interactions with environmental factors are elements that will help personalized medicine clinicians to produce better diagnostics and drugs, and select much better treatments and dosages based on individual needs not as just fixing a pill or two, as is the present-day conventional medical practice.

It is established that a majority of genes function precisely as intended. This gives rise to proteins that play a significant role in biological processes while allowing or helping an individual to grow, adapt and live in their environment. It is only in certain unusual situations, such as a single mutated or malfunctioning gene, that our apple cart is disturbed. This leads to distinct genetic diseases or syndromes such as sickle cell anemia and cystic fibrosis. In like manner, multiple genes acting together can impact the development of a host of common and complex diseases, including our response to medications used to treat them.

New advances will revolutionize bespoke medical treatment with the inclusion of drug therapy as well as recommendations for lifestyle changes to manage, delay the onset of disease or reduce its impact. Not surprisingly, the emergence of new diagnostic and prognostic tools has already raised our ability to predict likely outcomes of drug therapy. In like manner, the expanded use of biomarkers biological molecules that are associated with a particular disease state has resulted in more focused and targeted drug development.

Molecular testing is being expansively used today to identify breast cancer and colon cancer patients who are likely to benefit from new treatments and to preempt recurrences. A genetic test for an inherited heart condition is helping clinicians to determine which course of treatment would maximize benefit and minimize serious side effects while bringing about curative outcomes.

Such complexities exist for asthma and other disorders too. This is precisely where molecular analysis of biomarkers can help us to identify sub-types within a disease while enabling the clinician to monitor their progression, select appropriate medication, measure treatment outcomes and patients response. Future advances may make biomarkers and other tools affordable and allow clinicians to screen patients for relevant molecular variations prior to prescribing a particular medication.

It is already clear that personalized medicine promises three strategic benefits. In terms of preventative medicine, personalized medicine will improve the ability to identify which individuals are predisposed to develop a particular condition. A better understanding of genetic variations could also help scientists identify new disease subgroups or their associated molecular pathways and design drugs to target them. This could also help select patients for inclusion, or exclusion, in late-stage clinical trials. Finally, it will allow to work out the best dosage schedule or combination of drugs for each individual patient.

Yet not everything is hunky-dory for personalized medicine. Critics of precision medicine believe that the whole idea is too much of overhyped razzmatazz, among other things. Proponents, however, argue that when it comes to managing our own health, most of us are used to the idea of taking a one-size-fits-all approach be it medicines, supplements, diets and diagnoses. This may be wrong.

What works, as they put it, for one may be a gaffe for another. As the award-winning oncologist and medical technology innovator, Dr. David B. Agus, author of the groundbreaking bookThe End of Illness, puts it, each patients individual risk factors are based on ones DNA, the environment and a preventative lifestyle plan in response. He begins with simple, profound pointers: How is your sense of smell? and Is your ring finger longer than your middle finger? He explains with statistics-backed guidelines that moving and walking regularly is mandatory because exercising and then sitting is equivalent to smoking cigarettes, while eating and sleeping at consistent hours is imperative because irregularity causes inflammation.

The inference is obvious: We should all understand our physiology and quiz doctors with the thorough, exploratory frame of mind of a gadget buyer. This holds the key to making medicine truly personal, more humane, effective and safe while keeping in mind the individual in us all as unique and distinctive, the sum of the whole not just the parts.

The views expressed in this article are the authors own and do not necessarily reflect Fair Observers editorial policy.

Follow this link:
The Future of Medicine Is Bespoke - Fair Observer

Research on Gene Editing Service Market (impact of COVID-19) with Top Players: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine,…

Global Gene Editing ServiceMarket: Trends Estimates High Demand by 2027

The Gene Editing ServiceMarket 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Gene Editing ServiceIndustry Report is an in-depth study analyzing the current state of the Gene Editing ServiceMarket. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Gene Editing ServiceMarket provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Gene Editing Servicemarket. All findings and data on the global Gene Editing Servicemarket provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Gene Editing Servicemarket available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Gene Editing Serviceindustry.

Some of The Companies Competing in The Gene Editing ServiceMarket are: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine, Thermo Fisher Scientific, Horizon Discovery, Genscript Biotech, GeneCopoeia, Integrated DNA Technologies, Eurofins Genomics, DNA 2.0 (ATUM), BBI Life Sciences, Genewiz, Gene Oracle, SBS Genetech, and Bio Basic

Get a Sample Copy of the[emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-gene-editing-service-market-size-status-and-forecast-2020-2026?utm_source=primefeed&utm_medium=15

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Gene Editing ServiceMarket; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

GlobalGene Editing ServiceMarket Research Report 2020 carries in-depth case studies on the various countries which are involved in the Gene Editing Servicemarket. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Gene Editing Servicemarket report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Gene Editing Servicemarket into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Gene Editing Servicemarket scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Gene Editing ServiceMarket Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Gene Editing ServiceMarket Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Gene Editing ServiceMarket Effect Factors Analysis

Chapter 12: GlobalGene Editing ServiceMarket Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-gene-editing-service-market-size-status-and-forecast-2020-2026?utm_source=primefeed&utm_medium=15

About Us:

Reports And Marketsis part of theAlgoro Research Consultants Pvt. Ltd.and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read the original here:
Research on Gene Editing Service Market (impact of COVID-19) with Top Players: Caribou Biosciences, CRISPR Therapeutics, Merck KGaA, Editas Medicine,...

28 cool health things that started with a Canadian – Regina Leader-Post

A special thank you to Kathleen Dickson and Dr. John Bergeron for pointing out that yes, indeed, there are also many women who have made and continue to make significant contributions to health. We have added their additions below, but this list is by no means complete.

From open heart surgery to child-resistant containers, prestigious awards and bombs (not that kind), Canada has a long history of Canadians whose ideas and inventions have played huge roles in defining this nations healthcare.

DNA and cancer

Nada Jabado at McGill affiliated Childrens Hospital is a pioneer in pediatric cancer and her discovery of the role of what is known as the epigenome that marks the DNA in our genes in cancer. She is a leader in innovation in Health research and recognized for her leadership in the application of discoveries to address brain tumours in children.

Insulin

Perhaps the most famous health innovation to come out of Canada, if such a thing can be measured. The arrival of insulin has saved countless lives since its creation in 1922 when Frederick Banting and Charles Best isolated and extracted insulin from the pancreas of dogs. Their Nobel Prize arrived swiftly thereafter in 1923.

Link:
28 cool health things that started with a Canadian - Regina Leader-Post

Speaking Out: Taking Action Against Skin Cancer – Curetoday.com

Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.

BY By Beth Fand Incollingo and Kristie L. Kahl

In an interview with CURE, Dr. Jeremy Brauer, a dermatologist at NYU Langone Health in New York City and a spokesperson for the Skin Cancer Foundation, reviewed the latest strategies for treating these cancers, which include squamous cell and basal cell carcinomas, as well as the less common but more aggressive melanoma.

CURE: What surgical strategies are used to treat skin cancers?

Brauer: The intervention with the highest cure rate for surgical procedures is Mohs micrographic surgery. This is ideal for nonmelanoma skin cancers specifically, but there also is growing interest and use in certain melanomas, depending on the skin cancer and its location.

(Tissue is removed and tested a little at a time until the area being treated is free of cancerous cells).

Theres no leaving the office and waiting a week for your results; everything is done on-site in real-time. We process the tissue, and a Mohs surgeon also functions as the pathologist to read the slides and map out where the tumor is or isnt. The benefit of this is that it allows for tissue conservation, (especially on) the tip of the nose and ears. Also, it has a higher cure rate with the good cosmetic outcome because you are sparing tissue.

Another surgical intervention is a standard excision. You excise, take a big piece of skin and put stitches in, just like you would with Mohs, but its not a staged procedure. In general, its just one procedure.

Could you describe some of the nonsurgical therapies?

Nonsurgical treatments include electrodesiccation and curettage. These tend to be reserved for individuals who have a superficial basal cell carcinoma or what we call in situ squamous cell carcinoma, where the lesion is very superficial and on the uppermost part of the skin. Here, we use a sharp tool called a curette to scrape the area of involvement, but we also use electrodesiccation to burn the surrounding skin. This is often repeated in series a few times to remove the majority, if not all, of the tumor.

The goal here is to avoid having to cut and sew. The drawback is that you cant evaluate the tissue under the microscope because youre scraping and burning the remaining tumor cells.Another nonsurgical option is radiation therapy. This is sometimes used in conjunction with surgical treatment if it is determined that the subtype of skin cancer warrants it.

If involvement of the nerves is found during the course of Mohs surgery or when the specimen comes back after incision, we refer the individual to receive concurrent radiation therapy.

Radiation therapy is also good for (skin cancer that is not being treated with surgery). In certain instances, the individual might not able to tolerate (surgery) or declines the procedure. Similarly, certain tumors that dont heal well may be better candidates for a nonsurgical option.

Which medical options do you consider the most exciting?

I really do believe immunotherapy and targeted therapies for metastatic disease have been game changers. We consider immunotherapy an option for melanoma. Its been a game changer for ... survival in advanced cancers. That has definitely prolonged life for many individuals who unfortunately otherwise would not have fared as well.

Another interesting and promising area is targeted therapy. Here, were looking at the identification within the tumor of a mutation, specifically in a gene or pathway, and then targeting that gene or pathway (with medication). This has also led to increased survival rates and really allowed for a change in the way we approach some of the more advanced tumors.

That said, early intervention is key. Once weve detected these skin cancers, early intervention results in very high cure rates and, hopefully, prevents some of these local tumors from becoming metastatic or advanced.

What is on the horizon for patients with skin cancer?

Patients can be encouraged by the fact that medicine, technology and innovation are all moving at a very fast pace. More immunotherapy and targeted therapies will be made available to individuals with metastatic melanoma and advanced squamous cell carcinoma.

Also, right now, a biopsy is invasive. There is numbing and taking a blade to the skin. But there are other imaging techniques, and as our ability to detect skin cancer becomes better and greater, well begin to see additional noninvasive biopsy techniques.

How can patients become empowered to be their own best advocates when making treatment decisions?

It starts with education. Knowledge is power. A great resource is a board-certified dermatologist, who can discuss in detail the diagnosis and expectations. Also, reputable websites like that of the Skin Cancer Foundation offer information. Within dermatology, the American Academy of Dermatology and other societies can be great resources.

Going back to prevention, people need to understand that skin cancer is serious. You can die from skin cancer. But the good news is that these are preventable tumors and cancers. You have to take action to prevent it.

How do you do that? (It takes) appropriate use of UVA- or UVB-spectrum sunscreen, sun-protected behaviors when outdoors and screening, not just seeing a dermatologist once a year but also doing monthly self-skin examinations. Look for something new, unusual or changing and bring that to the attention of a dermatologist. Early detection results in early intervention, which results in very high cure rates.

More here:
Speaking Out: Taking Action Against Skin Cancer - Curetoday.com

Pools in the Mexican desert are a window into Earth’s early life – Science Magazine

Azure pools rich in magnesium and calcium carbonate but low in phosphorus provide an ideal habitat for ancient bacterial reefs at Cuatro Cinegas, in theChihuahuan Desert of Mexico.

By Rodrigo Prez Ortega Jun. 30, 2020 , 3:40 PM

Valeria Souza Saldvar never planned to devote her life to a remote and ancient oasis more than 1000 kilometers north of her laboratory in Mexico City. But a call in early 1999 changed that.

Its one of the best cold calls Ive ever made, says James Elser, a limnologist at the University of Montana. He had picked up the phone to invite Souza Saldvar to join a NASA-funded astrobiology project in Cuatro Cinegasa butterfly-shaped basin with colorful pools, or pozas, in the middle of Mexicos Chihuahuan Desert.

Neither Souza Saldvar, a microbial ecologist at the National Autonomous University of Mexico, University City, nor her ecologist husband and research partner Luis Eguiarte Fruns, also at UNAM, had ever visited Cuatro Cinegas. That first trip convinced them to completely change their research plans. Looking at those mountains and the water, I fell in love, Souza Saldvar says.

The landscapemore than 300 turquoise-blue pozas scattered across 800 square kilometers, among marshes and majestic mountainswasnt the only draw. The waters, whose chemistry resembled that of Earths ancient seas, teemed with microbes; unusual bacterial mats and formations called stromatolites carpeted the shallows. When Souza Saldvar first cultured the organisms from the pozas, The amount of microbes was enormous, as was the diversity of colors and colony sizes, she recalls. For her, this remote microbial hot spot was an irresistible mystery.

Since then, work by Souza Saldvar, Eguiarte Fruns, and a widening circle of collaborators in Mexico and the United States has shown that Cuatro Cinegaswhich means four marshes in Spanishis one of the most biodiverse places on the planet. Theres nowhere that has so much ancient diversity of microorganisms, says Michael Travisano, an evolutionary ecologist at University of Minnesota, Twin Cities, who has collaborated with the Mexican researchers since 2001. Among the most recent additions to that menagerie are hundreds of species of archaea, the ancient microbes that may have given rise to eukaryotesorganisms with complex, nucleated cells.

At the Pozas Azules ranch in Cuatro Cinegas, about 100spring-fed pools dapple the desert. Each has a unique microbial and mineral composition.

The diversity includes strains with unusual adaptations, such as the ability to build their lipid membranes with sulfur instead of the usual phosphorus, which is scarce in the waters of thepozas. It includes potential sources of new compounds for medicine and agriculture. And it poses a question that has occupied Souza Saldvar and Eguiarte Fruns for the past 20 years: How did this Noahs Ark of ancient microbes arise? Its a dream for every biologist to know the origin of diversification, Souza Saldvar says.

But her dream might be short-lived. Since the 1970s, farmers have intensively drained water from thepozasand rivers to irrigate nearby fields of alfalfa, grown for cattle fodder, gradually drying the improbable oasis. Souza Saldvar has galvanized a conservation effort that has slowed the drainage; in the coming weeks, a canal that removes 100 million cubic meters of Cuatro Cinegass water annually is scheduled to close. In the meantime, the researchers have been trying to describe as much as they can, as fast as they can, before their belovedpozasdry up and the precious microscopic life that has survived undisturbed for millions of years dies off.

Cuatro Cinegasservedas a stopping point for hunter-gatherers for thousands of years. To date, 50 archaeological sites with cave paintingssome dating to 2275 B.C.E.have been found in mountain cavesaround the basin. Much later, the region made a mark on history when Venustiano Carranza, born in a village at the basins margin, became a leader of the Mexican Revolution and president of Mexico from 1917 to 1920. Nowadays, the village is called Cuatro Cinegas de Carranza after him.

But in the 1960s, Cuatro Cinegas started to become famous for its biodiversity, as biologists began to describe new species of snails, fish, turtles, and plants found in the pools and marshesand often nowhere else.

Wendell Minck Minckley, a renowned ichthyologist at Arizona State University (ASU), Tempe, was first lured to Cuatro Cinegas after learning thatthe worlds only aquatic box turtle(Terrapene coahuila) lived there. Over the years, Minckley made frequent trips to thepozas, describing their snails and fish (Herichthys minckleyi, a cichlid, bears his name) while making connections with the local people.

In the Cuatro Cinegas Basin, ringed with mountains and desert, an aquifer feeds hundreds of pools and marshes. But canals tapping water for agriculture threaten the wetlands and the biodiversity they host.

(MAP) N. DESAI/SCIENCE; (DATA) E. MAMER AND T. NEWTON/NEW MEXICO BUREAU OF GEOLOGY AND MINERAL RESOURCES; VALERIA SOUZA SALDVAR; NATIONAL COMMISSION OF NATURAL PROTECTED AREAS MEXICO

Minckley also noticed peculiar, rocky structures in the pools. They were stromatolites, biological structures normally found as fossils dating back as much as 3.5 billion years. Colonies of photosynthesizing bacteria, which boosted early Earths oxygen, created the layered formations by depositing carbonates and trapping sediment in ancient, shallow seas. But these stromatolites were alive. Also found in other extreme environments such as Australias warm, salty Shark Bay, living stromatolites are sort of a window into early Earth, Elser says. Thepozasalso nurture bacterial mats, a soft form of stromatolites normally found deep in the ocean.

As early as the 1970s, Minckley realized the pools and their diversity were under threat: Local farmers were carving canals to tap their water. Thanks in part to his lobbying, the Mexican government in 1994 designated an 85,000-hectare protected area. But the drainage continued. Minckley knew that Cuatro Cinegas was going to die, Souza Saldvar says. He thought NASA might be its salvation.

In 1998, NASA established its Astrobiology Institute, a network of researchers studying life in extreme environments that might resemble conditions on other planets. Minckley saw an ideal astrobiology study site in the waters of thepozas, with their seemingly inhospitable chemistry and living stromatolites. But he was no expert on extreme environments, so he enlisted Elser, who specializes in how water chemistry affects ecosystems and also works at ASU. After they submitted a 1998 proposal to fund the project, however, NASA said they should add experts on microbiology and evolutionand those experts had to be Mexican to help secure permits to obtain samples. Based on colleagues suggestions, Elser called Souza Saldvar and Eguiarte Fruns, newly minted professors at UNAM. They joined, and NASAapproved the 3-year project.

Stromatolites, reeflike colonies of carbonate-secreting cyanobacteria, abounded in Precambrian seasand thrive at Cuatro Cinegas.

With two children in tow, the couple met Minckley and Elser at Cuatro Cinegas. Next to the turquoise-blue waters of La Becerrapoza, Minckley told them he believed the ecosystem was a glimpse of deep time. Do you see these miniature snails in my hand? Souza Saldvar recalls him saying. I just scooped them from the springhead, but their direct ancestors were eating sulfur bacteria in hydrothermal vents 220 million years ago in the bottom of the ancient Pacific.

Based on the water chemistrylow in phosphorus, iron, and nitrogenand the presence of living stromatolites, Minckley believed Cuatro Cinegas re-created the marine conditions found worldwide millions of years ago. He challenged the two researchers to explore its mysteriesand to protect itspozas. Only you, as Mexicans, can save them from the extinction caused by humans, Souza Saldvar recalls him saying.

Minckleydied2 years later, in 2001.

To inventory the full diversityof microbes at Cuatro Cinegas and trace their relationships, Souza Saldvar needed to study their DNA. To do so, scientists normally take microbial samples from a site and grow them in a lab. But many bacteria and archaea are difficult to culture, and only a few groups at the time had successfully analyzed DNA isolated directly from the environment. High magnesium levels in the water and slime from the microbes made isolating DNA from thepozasespecially difficult.

But Souza Saldvar and her students Ana Escalante and Laura Espinosa Asuar made a start. In 2006, they reported in theProceedings of the National Academy of Sciencesthat they had found 38 distinct groups of microbesfour times as many as in a typical salt marshcorresponding to 10 major lineages of bacteria and one of archaea. Half the bacterial groupswere most closely related to marine microbes. Almost 10% of the groups resembled ones that live on hydrothermal ventsfissures deep in the ocean where microbes thrive despite extreme heat and mineral concentrations.

As Minckley had suspected, Cuatro Cinegas had somehow preserved ancient marine life forms deep in the desert, more than 500 kilometers from the Gulf of Mexico, at a site where the last seas retreated some 20 million years ago.

Valeria Souza Saldvar and Luis Eguiarte Fruns (top) have spent 20 years studying biodiversity at Cuatro Cinegas, where they have found thousands of new species in living structures like a bacterial mat (bottom).

The deep time aspect [of Cuatro Cinegas] is very surprising, Travisano says. It is a true lost world, preserved by the hostile water chemistry, he and the Mexican team argued in a 2018 paper ineLife. Millions of years ago, they proposed, ancient marine ancestors found their way to the place,adapted to the extreme environment, and didnt change much.

Thepozasthemselves are not particularly ancient. The springs that nurture them are fed by deep aquifers in Sierra San Marcos y Pinos, filled with water accumulated during the last ice ages, Eguiarte Fruns says. Now, the water seeps to the surface because of an active fault beneath the basin. It rises through ancient marine sediments, picking up its unusual chemistry along the way. Somehow, the ancient microbespersisted and diversifiedin a succession of springs that must have appeared and vanished throughout geologic time. As in an ancient clock, Souza Saldvar says, all the original mechanisms are still working together to sustain unusual life.

To Frederick Cohan, a microbial ecologist at Wesleyan University who is not part of the Cuatro Cinegas project, the fact that many of the microbes are related to marine species and not species found inland is compelling. I think its saying those organisms are anciently there.

When the researcherslooked at the stromatolites, theyfound even more diversity. Samples from one site, Pozas Azules II, yielded more than 58,000 distinct microbial sequences, predominantly from bacterianot a direct count of species, but an indicator of biodiversity. In the Ro Mezquites, a stream that flows through the northern part of the basin and recharges several pools, they identified 30,000 sequences, mostly from cyanobacteria. More than 1000 sequences from Pozas Azules II appeared to be from archaea, the researchers reported inEnvironmental Microbiologyin 2009. The stromatolites also teemed with bacteria-infecting virusesstrains that wereunique to each pooland resembled marine viruses.

Studying the microbes hasnt been easy. There are thousands and thousands of new bacteria that we cant grow in culture, Souza Saldvar says. They could, however, identify some startling adaptations to the extreme conditions. In one bacterium found only in El Churince, a system of lagoons andpozason the western part of the basin, researchers sequenced the smallest genome ever found in its genus,Bacillus. The work, led by Gabriela Olmedo lvarez, a genetic engineer at Center for Research and Advanced Studies of the National Polytechnic Institute, Irapuato, also showed that the microbeB. coahuilensiscould synthesize membrane sulfolipids. This meant that, like some plants and cyanobacteria, it could use sulfur from the environmentinstead of phosphorusto form its cell membranes.

Shallow, mineral-rich pools and lagoons, with conditions like those in ancient oceans, are hot spots of microbial diversity. Floating mats at Cuatro Cinegas teem with the primordial microbes known as archaea, leading researchers to call them archaean domes.

(GRAPHIC) N. DESAI/SCIENCE; (DATA) GARCIA-MALDONADO ET AL., EXTREMOPHILES, DOI 10.1007/S00792-018-1047-2; CENTENO ET AL., MICOBIOLOY ECOLOGY, DOI: 10.1111/J.1574-6941.2012.01447

It likely stole these genes from a cyanobacterium, Olmedo lvarez says, enabling it to cope with scarce phosphorus, a condition thought to have prevailed in Earths earliest oceans. The microbes small genome may also have helped it thrive, as it required less phosphorus to build its DNA. Olmedo lvarez thinks the organism may offer a glimpse of the stratagems used by early microbes to adapt to their new environment.

Were just starting to understand the depth of diversity, says Olmedo lvarez, who found thatB. coahuilensisis itself starting tosplit into strainswith variations in phosphorus metabolism.

The low phosphorus conditions found in Cuatro Cinegas not only promoted local adaptations, but alsoaccelerated microbial diversification, Souza Saldvar and Elser argued in a perspective published in 2008 inNature Reviews Microbiology. Bacteria normally share bits of DNA with their neighbors in a process called horizontal gene transfer, which blurs the divisions between strains. But in Cuatro Cinegas, the microbeshungry for phosphorusessentially consume free DNA rather than incorporating it into their genomes. They will eat the DNA to get the phosphorus, Elser says.

Besides offering insights into evolution, Cuatro Cinegass microbial diversity may hold practical payoffs. Cuatro Cinegas is one of the richest places on the planet for genetic resources, Souza Saldvar says. For example, most modern antibiotics are derived from actinobacteria, which are abundant in thepozas. Susana De la Torre Zavala, a biotechnologist at the Autonomous University of Nuevo Len (UANL), University City, is searching for potential antibiotics in a library of 350 actinobacteria from the basin. Her team has also found that an extract from a microalga living in the poolsshows anticancer activity.

Agriculture, too, could benefit, Olmedo lvarez says. By 2050, the reservoirs of phosphorus that help sustain global harvests could become scarce, and the microbesability to concentrate the element from different sourcescould hold solutions. Were understanding Cuatro Cinegas, but were also understanding basic principles of ecological interactions that have an application in medicine and agriculture, she says.

As the scientific storyof Cuatro Cinegas unfolded, its fate has hung in the balance, with Souza Saldvar fighting a long series of battles over its water with local farmers and landowners, dairy companies, and politicians. Her weapons have been her rising scientific profile and a tireless outreach to the public, especially young people.

Souza Saldvar has drawn fireduring a 2013 microbiology congress, police had to protect her from protesting localsbut she has won a series of victories. In 2007, the daughter of the CEO of LALA, a giant dairy consortium with roots in the state of Coahuila, told her father she wouldnt speak to him because he was killing Cuatro Cinegas, Souza Saldvar says. The executive promptly scheduled a meeting with the scientist. You need to change your cows diet, Souza Saldvar says she told him, refusing to accept a courtesy yogurt he offered. Ill accept your yogurt when you do so. He promised not only to stop buying the regions alfalfa, but also to invest in environmental education projects for local children.

Two years later, she won an unusual ally, the powerful Mexican billionaire Carlos Slim. His foundation collaborated with the World Wildlife Fund (WWF) to buy the land surrounding El Churince in the western basin, and to provide researchers with a 5-year, 18 million Mexican peso ($1.4 million) grant to study Souza Saldvars favoritepoza. This allowed them to set up the infrastructure to perform long-term experiments. But it did not save the water.

Endemic fishes and turtles first drew scientists to Cuatro Cinegas, where they stumbled on its less visible microbial riches.

In 2010, Mexicos National Water Commission (CONAGUA) set out to replace the open, leaky canals, which lose 75% of the drained water, with less wasteful enclosed conduits. But the project was abandoned midwaymost likely because of corruptionand the old canals were never closed. As Cuatro Cinegas continued to dry up, the researchers raced to study El Churince, finding 5167 distinct species of bacteria and archaea in the last remaining pool. A close inspection of the genomes ofBacillusbacteria from one single square kilometer increased the known diversity of the group by more than 20%. By comparing DNA sequences, the team traced theBacillusdiversity to two ancient ancestors, one dating back 680 million years, the other 160 million years. Those dates coincide with the breakup of the supercontinents Rodinia and Pangaea, respectively, and the team thinks theoceans that formed during those convulsions carried the ancestral microbesto what is now the Cuatro Cinegas Basin, where they have persisted ever since.

Cohan says thats plausible.Bacillusfrom elsewhere fail to thrive in Cuatro Cinegas, most likely because they are outcompeted by the local microbes and cant adapt to the extreme conditions. And theBacillusspecies from Cuatro Cinegas are not found anywhere else in the world. Its just bizarre, Cohan says, but it makes thepozasso much more valuable and worth saving. Its kind of a paleontological microbial park.

In 2016, El Churince dried up just after the funding from the WWFCarlos Slim Foundation ended. The researchers felt devastated. Souza Saldvar says it was painful to see turtle shells lying on the now-barren soil. Its really sad, Olmedo lvarez says. Its gone.

On the eastern sideof the basin, things are looking brighter. In 2000, the conservation nongovernmental organization Pronatura Noreste acquired the Pozas Azules ranch: 2721 hectares hosting about 100pozas. Pronatura eventually gained rights to the water as well, enabling it to close canals draining thepozasin the ranch. Farmers are now encouraged to adopt water-sparing drip irrigation, and some are growing nopalan edible cactus popular in Mexican cuisinewhich requires much less water than alfalfa.

The researchers have focused their recent studies on Pozas Azules. In 2019, after an unusual spring rain, the team noticed alien-looking structures in the shallow waters of a site near Pozas Azules II: white microbial mats buoyed by gas. The gas appeared to be largely methane, and a genetic analysis showed the mats were teeming with archaea230 distinct species,they report in a preprint. That makes the spot the most diverse place of archaea that we know of, De la Torre Zavala says.

Now, the team hopes to analyze samples from the structures, which it calls archaean domes, in search of the elusive Asgard archaea, organisms previously found only in the deep ocean and thought tohold clues to the evolution of simple microbesinto complex eukaryotes. Although some in her team are skeptical, Souza Saldvar is convinced they will find them. Valerias usually right, De la Torre Zavala says.

Shaped and seeded with life by ancient seas, the Cuatro Cinegas Basin lies at the foot of the distant Sierra San Marcos. The white dunes bordering the basin are made of gypsum, a legacy of a Jurassic ocean.

Such prospects have added to Souza Saldvars determination to preserve Cuatro Cinegas, and she is enlisting young people for support. In every field trip since 2004, her team has spent time with students from the local high school, showing them how to use a microscope and take simple environmental measurements, and teaching them about sustainable agriculture. In 2011, with funding from the LALA Foundation and the WWFCarlos Slim Foundation, the scientists set up a college-level molecular biology lab at the school, which is now ranked among the best rural high schools in Mexico.

Hctor Arocha Garza is one of its graduates. Inspired by the secrets of Cuatro Cinegas, he pursued a Ph.D. in biotechnology at UANL with De la Torre Zavala, then returned to his hometown. My heart was in Cuatro Cinegas, he says. Now, hes leading the scientific branch of a privately fundedmegaproject called Cuatro Cinegas 2040that aims to build a science museum and make Cuatro Cinegas a scientific tourism destination, while supporting education and medical care for the villages young people.

The effort comes at a critical moment. More than 90% of the marshes are gone, and somepozasand lagoons are dry. But this year, CONAGUA committed toregulating water usageand closing illegal wells, and Pronatura Noreste will close the Saca Salada Canal, which drains the Ro Mezquites, as soon as the COVID-19 pandemic permits.

Those developments, and stories like Arocha Garzas, give Souza Saldvar hope for the future of Cuatro Cinegas. It has been a very complicated, long, and difficult process, she says. But now, she wrote in a recent book, There is a revolution occurring in this oasis: Science is the tool and kids are the drivers.

Follow this link:
Pools in the Mexican desert are a window into Earth's early life - Science Magazine

Nanotechnology shown to slow spread of COVID-19 virus in lung and white blood cells, study shows – cleveland.com

SAN DIEGO, California A promising technology slowed the spread of SARS-CoV-2, the virus that causes COVID-19, in cell cultures, researchers at the University of California San Diego and Boston University found in lab experiments.

The United States led the world in coronavirus cases with 2.7 million confirmed Thursday, according to data maintained by Johns Hopkins University.

Engineers at UC-San Diego coated tiny nanoparticles made of polymer with lung and white blood cell membranes, disguising them as human cells to the virus.

The membranes covering the nanoparticles had the same external receptors and proteins that the virus uses to enter the human lung and white blood cells. The nanoparticles fooled the SARS-CoV-2 virus into thinking they were human cells and the virus bound onto them. Once attached to the nanoparticles, the virus could no longer enter a human cell or reproduce.

These lung cells and white blood cell nanoparticles blocked almost 90 percent of the virus ability to enter human cells, reproduce and create more virus in lab dish experiments, researchers out of UC San Diego and Boston University published last month in Nano Letters.

Nanoparticles were first masked as human cells, like red blood cells, more than a decade ago at UC San Diegos Jacobs School of Engineering. They can also be used to extract oil or toxins from water or an oil spill. They have to be masked to be used in the body because the immune system attacks foreign objects. They have been dubbed nanosponges by researchers because of their ability to soak up pathogens or toxins.

Researchers at UC-San Diego will work next to see how well the COVID-19 nanosponges work in animals, and potentially, in humans.

Its a very promising technology, but I think its still very early to know how effective it will be in humans, said Vijay Krishna, assistant staff at the Cleveland Clinics biomedical engineering department. He has studied nanoparticles but is not an author or contributor to this study.

Usually, it would take between five and 10 years to develop this kind of technology for use in humans, Krishna said. But these are not normal times, and the development time for use in humans could speed up to one or two years.

The way these nanoparticles react in the cells in a lab is very different than how they might respond in living organisms, Krishna said.

Working in cells is very different than working in a living organism, he said. In a lung there is a lot of dynamics of movement, from your breathing, from blood flow and lungs expanding and contracting. These dynamics can change the interactions of nanosponges with the virus and that can actually dictate how effective these nanoparticles are.

Here is the original post:
Nanotechnology shown to slow spread of COVID-19 virus in lung and white blood cells, study shows - cleveland.com

Translation of the long-term fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine – DocWire News

This article was originally published here

Liang C, et al. Sci China Life Sci 2020 Review.

ABSTRACT

Many years of fundamental studies on viral genome packaging motors have led to fruitful applications. The double-stranded DNA (dsDNA) viruses package their genomes into preformed protein shells via nanomotors including several elegant and meticulous coaxial modules. The motor is geared by the hexameric RNA ring. An open washer displayed as hexametric string of phi29 motor ATPase has been reported. The open washer linked into a filament as a queue with left-handed chirality along the dsDNA chain. It was found that a free 5- and 3-dsDNA end is not required for one gp16 dimer and four monomers to assemble into the hexametric washer on dsDNA. The above studies have inspired several applications in nanotechnology and nanomedicine. These applications include: (i) studies on the precision motor channels have led to their application in the single pore sensing; (ii) investigations into the hand-in-hand integration of the hexametric pRNA ring have resulted in the emergence of the new field of RNA nanotechnology; and (iii) the studies on the motor stoichiometry of homologous multi-subunits that subsequently have inspired the discovery of new methods in highly potent drug development. This review focuses on the structure and function of the viral DNA packaging motors and describes how fundamental studies inspired various applications. Given these advantages, more nanotechnological and biomedical applications using bacteriophage motor components are expected.

PMID:32617827 | DOI:10.1007/s11427-020-1752-1

See the rest here:
Translation of the long-term fundamental studies on viral DNA packaging motors into nanotechnology and nanomedicine - DocWire News

Global Nanotechnology and Nanomaterials Market is Poised To Achieve Continuing Growth During Forecast Period 2020-2027 – Daily Research Chronicles

The Global Nanotechnology and Nanomaterials Market report gives a detailed overview of the key market drivers, restraints, and trends and analyzes the way they will affect markets development over the forecast period 2020-2027

This Global Nanotechnology and Nanomaterials Industry 2020 report also gives comprehensive insight of , in-depth overview of the competitive landscape of the Nanotechnology and Nanomaterials Market, Industry Size, Share, Market Productions, Pricing, Global Revenues 2018-2020 Import-Export Figures & SWOT Analysis, PEST analysis, PORTER analysis and Forecast till 2027

Get/Download Free sample report,(Including COVID19 Impact Analysis, full TOC, Tables and Figures) @https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-nanotechnology-and-nanomaterials-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58541#request_sample

Nanotechnology and Nanomaterials Market Influencing Factors:

Nanotechnology and Nanomaterials Market Forecast (2020-2027):

(Exclusive Offer: Up to 20% discount on this report):- Ask For Discount https://www.reportspedia.com/discount_inquiry/discount/58541

The leading players of Nanotechnology and Nanomaterials market includes

Clariant International LimitedHosokawa Micron GroupAccess Pharmaceuticals IncorporatedAlmatis GmbHAMCOL International CorporationEastman Kodak CompanyBioDelivery Sciences International IncorporatedNanoOptoCompetitive Technologies IncorporatedEvident TechnologiesQuantum Dot CorpZyvexAltair Nanotechnologies IncorporatedNanosys Inc.NanoViricidesNanomatSuperior Micro ProductsTeva Pharmaceutical Industries LimitedFrontier Carbon CorporationAbbott LaboratoriesNanodynamicsDendritic NanoTechnologies, Inc.Nanophase Technologies CorporationHyperion Catalysis International IncorporatedSun Nanotech Company Limited

Nanotechnology and Nanomaterials Market Segmentation

Type Analysis of Nanotechnology and Nanomaterials Market:

Carbon nanotubesNanoclaysNanofibersNanosilverQuantum DotsSilicon Oxide NanopowderTitanium DioxideZinc OxideNanoporous Materials

Applications Analysis of Nanotechnology and Nanomaterials Market:

AerospaceAutomotiveElectronics and SemiconductorsMedical and Life SciencesSensorsMilitary and Defense,

Any Quries Or Customization? Do Inquiry Here https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-nanotechnology-and-nanomaterials-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58541#inquiry_before_buying

Globally, Nanotechnology and Nanomaterials market spread across-

1. North America Country (United States, Canada)

2. South America

3. Asia Country (China, Japan, India, Korea)

4. Europe Country (Germany, UK, France, Italy)

5. Other Country (Middle East, Africa, GCC)

Segment 1. Nanotechnology and Nanomaterials Market Overview, Market Scope, Size Estimation, and Market Segmentation.

Segment 2. Nanotechnology and Nanomaterials Growth Drivers, Opportunities, Emerging Segments, and Industry Plans and Policies are explained.

Segment 3. Nanotechnology and Nanomaterials Industry Chain Analysis Explaining Manufacturing Base, Market Share, Product Type, Upstream Raw Materials Suppliers, and Downstream Buyers Is Covered.

Segment 4. Nanotechnology and Nanomaterials segmentation by type explains growth rate , and value from 2015-2020

Segment 5. Nanotechnology and Nanomaterials segmentation by application and regions covers consumption, growth rate, market share, price, and gross margin analysis.

Segment 6. Production, Consumption, Import-Export analysis of Nanotechnology and Nanomaterials by regions is explained.

Segment 7. Market Status and regional SWOT Analysis, PEST analysis, PORTER analysis are described.

Segment 8. Competitive landscape structure of top Nanotechnology and Nanomaterials players, gross margin analysis, price, and production value is specified.

Segment 9. Nanotechnology and Nanomaterials market analysis forecast by volume, value, consumption from 2020-2027 is provided for type, application, and region.

Segment 10. Nanotechnology and Nanomaterials Market maturity analysis, consumption forecast, feasibility study, and valuable Insight.

For more Information or Browse the complete report @https://www.reportspedia.com/report/chemicals-and-materials/2015-2027-global-nanotechnology-and-nanomaterials-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58541#table_of_contents

Read more:
Global Nanotechnology and Nanomaterials Market is Poised To Achieve Continuing Growth During Forecast Period 2020-2027 - Daily Research Chronicles

What to do when the adults don’t have the answers – CNN

As my school ended in-person classes and my dinner table conversation became consumed with pandemic fears, I tried to channel my energy into doing something productive. As a person who has always been fascinated by nanotechnology -- the manipulation of matter at an extremely small scale -- I believed it could be used to potentially protect Americans from spreading the virus further.

After watching frontline workers make calls for more effective masks and hearing the struggles of health care professionals directly, I realized the great need for a lightweight mask that covers all orifices of the face. So, I began considering concepts I learned in my school's nanotechnology club and chemistry class, as well as reviewing several research articles from scientific journals. Several weeks later, I developed the idea for a nitrogen-doped graphene mask.

Though it has never been done before, the concept of a nitrogen-doped graphene mask isn't all that radical. On its own, graphene, which is a single-layered allotrope of carbon, is impermeable -- such that even a helium atom cannot pass through. However, when graphene is doped with nitrogen, some carbon bonds are broken in the graphene, thus opening up nanoscopic pores. These pores selectively allow oxygen to come in, theoretically making graphene masks breathable, yet acting as a barrier to Covid-19 particles, which are bigger than oxygen atoms.

While the possibility of manufacturing my mask -- assuming it proved to be medically sound -- at a scale necessary to combat the virus might be challenging, my hope is that my idea inspires others to think creatively about ways to tackle Covid-19. In particular, I hope it inspires my fellow Gen Z peers to recognize that we don't always need to turn to adults for the answers -- we may have a few of our own, too. And one of those ideas could save a life.

Parnika Saxena is a high school junior at the Thomas Jefferson High School for Science and Technology in Virginia.

College senior Alexis Day: When in doubt, turn to TikTok

Like millions of students across the country, my spring semester was interrupted by the pandemic. After quickly saying my goodbyes to my fellow classmates and professors at the University of San Diego, I found myself on a drive through the desert to Las Vegas, my hometown.

As my university worked to set up a virtual classroom system, I suddenly had some extra time on my hands. In an effort to not spend all of it scrolling through Instagram and bemoaning the many missed senior moments -- from graduation to department recognitions to senior week parties -- I tried to find a medium that could both speak to my disappointment and offer a brief reprieve from the chaos of the pandemic.

Enter TikTok, a platform that shares staged video clips of people or events in a minute or less.

And, after two months at home, I have made a few TikToks myself -- though I have only shared them with my closest friends and family. They've ranged from light-hearted skits or collaborations with friends to really poor attempts at learning viral dances.

TikTok groups high school and college seniors under "Class of 2020," so when I search for recent content, I see quite a range of stories -- and watching high school students several years my junior expressing their roller-coaster of emotions, but with their signature teenage sarcasm, makes me feel a bit more youthful and energized. In other words, even if I am physically isolated, I'm not alone in my experience -- and these days that virtual connection is priceless.

Alexis Day is a recent graduate of the University of San Diego, majoring in political science and communication studies.

Link:
What to do when the adults don't have the answers - CNN

Nanotechnology Drug Delivery Market is Projected to Reach US$ 118,527.2 Mn by 2023 – Science Examiner

The competitive landscape of the global nanotechnology drug delivery market is largely consolidated, with a small number of companies accounting for dominant share in the global market in 2014, observes Transparency Market Research in a recent report. However, the scenario is steadily changing as a number of new pharmaceutical companies foray into the nanotechnology drug delivery space in the lookout for innovative, more effective drug delivery techniques. The rising sums that new companies are investing in research and development in this field are allowing for a rise in R&D activities, helping the market expand at a steady pace.

Collaborations among leading pharmaceutical companies and technology developers is a trend that has picked pace in the market in the past few years. This is enabling massive improvements in clinical models used for evaluating the efficiency of nanomedicines. A number of companies are also focusing on the development of nanomedicines for the treatment of a variety of cancers. Some of the leading companies in the market are Amgen, Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Novartis AG, and AbbVie, Inc.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1822

The report predicts that the global nanotechnology drug delivery market will expand at an excellent 12.5% CAGR from 2015 and 2023. If the predictions hold true, the market will rise from a valuation of US$ 4.1bn in 2014 to US$11.9 bn by 2023.

North America to Remain Most Lucrative Regional Market

Of the key applications of nanotechnology drug delivery examined in the report, the oncology segment emerged as the contributor in terms of revenue in 2014. Demand for nanotechnology drug delivery is expected to be the highest in the oncology sector over the reports forecast period as well owing to the massive rise in prevalence of a number of cancers and the high demand for effective treatment methods for cancers across the globe.

Request for Analysis of COVID19 Impact on Nanotechnology Drug Delivery Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1822

Geography-wise, the market in North America accounted for the dominant share in the overall market in 2014. The region boasts a vast number of some of the worlds leading pharmaceutical companies, technology developers, and research institutions. Moreover, the massive rise in incidence rate of a number of chronic diseases has compelled governments in developed countries in the region to encourage R&D activities and the development of more effective ways of treating common diseases.

Vast Rise in R&D Activities Enable Development of New Drug Delivery Models

The global market for nanotechnology drug delivery is chiefly driven due to a host of factors, including advancements in nanotechnology, which have revolutionized the field of drug delivery, the rising prevalence of infectious diseases, a variety of cancers, and numerous chronic ailments, and the rising demand for novel and more effective drug delivery systems. The vast rise in research activities in the field of nanotechnology, which has enabled the discovery of several new and more effective varieties of imaging and therapeutic agents and thus the development of more reliable diagnostics and therapeutic options, are also spelling growth for the market.

Buy Nanotechnology Drug Delivery Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=1822&ltype=S

However, the markets growth is limited by a certain degree owing to the uncertain regulatory scenario pertaining to the approval of nanotechnology products on a global front and the high cost of nanomedicines. The high cost of nanomedicines is especially a big challenge for the market when it comes to targeting emerging markets with cost-conscious consumers.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more here:
Nanotechnology Drug Delivery Market is Projected to Reach US$ 118,527.2 Mn by 2023 - Science Examiner

Enjoying the fireworks? You are watching chemistry in action! – WHNT News 19

When you are watching the fireworks this year, just think that is chemistry in action!

Okay, you may not be thinking about science and would rather focus on the show, but the spectacular colors and sizzling sounds wouldnt happen without it.

When we look up at the sky and see the rockets red glare, you can thank the element strontium for the ruby hue.

In fact, the majority of the colors you see are courtesy of various compound salts bursting in the air.

Red is formed when strontium salts are heated to extreme temperatures.

Orange fireworks get their glow from calcium, where as yellow is formed from sodium.

Green bursts of color are from barium, and copper compounds are responsible for the shimmery blue bombs bursting in air.

But if youd rather celebrate the holiday in your backyard with a big box of sparklers, behold that you are enjoying the sights and sounds of chemistry in your hand.

Sparkler rods contain a mixture of powdered metallic fuel, oxidizers and binder and whats in the fuel can result in different colors.

Aluminum and magnesium compounds produce yellow sparks; iron produces more bronzy hues, and titanium produces silvery sparks.

Oxidizers in the sparkler rod produce oxygen, which help the metallic fuel burn.

And of course, there are binding materials that hold everything together.

Have a safe and happy Fourth of July, and if you watch any fireworks this weekend I hope you enjoy the science show!

Christina

Connect with me!Facebook:Christina Edwards, WHNTTwitter:@ChristinaWHNTwx

View original post here:
Enjoying the fireworks? You are watching chemistry in action! - WHNT News 19